Kainer Marion A, Linden Jeanne V, Whaley David N, Holmes Harvey T, Jarvis William R, Jernigan Daniel B, Archibald Lennox K
Epidemic Intelligence Service, Division of Applied Public Health Training, Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, USA.
N Engl J Med. 2004 Jun 17;350(25):2564-71. doi: 10.1056/NEJMoa023222.
Allografts are commonly used in orthopedic reconstructive surgery. In 2001, approximately 875,000 musculoskeletal allografts were distributed by U.S. tissue banks. After the death from Clostridium sordellii sepsis of a 23-year-old man who had received a contaminated allograft from a tissue bank (Tissue Bank A), the Centers for Disease Control and Prevention initiated an investigation, including enhanced case finding, of the methods used for the recovery, processing, and testing of tissue.
A case of allograft-associated clostridium infection was defined as a culture-proven infection of a surgical site within one year after allograft implantation, from January 1998 to March 2002. We traced tissues to tissue banks that recovered and processed these tissues. We also estimated the rates of and risk ratios for clostridium infections for tissues processed by the implicated tissue bank and reviewed processing and testing methods used by various tissue banks.
Fourteen patients were identified, all of whom had received allografts processed by Tissue Bank A. The rates of clostridium infection were 0.12 percent among patients who received sports-medicine tissues (i.e., tendons, femoral condyles, menisci) from Tissue Bank A and 0.36 percent among those who received femoral condyles in particular. The risk-ratio estimates for clostridium infections from tissues processed by Tissue Bank A, as compared with those from other tissue banks, were infinite (P<0.001) for musculoskeletal allografts, sports-medicine tissues, or tendons. Because Tissue Bank A cultured tissues only after treating them with a nonsporicidal antimicrobial solution, some test results were probably false negatives. Tissues from implicated donors were released despite the isolation of clostridium or bowel flora from other anatomical sites or reports of infections in other recipients.
Clostridium infections were traced to allograft implantation. We provide interim recommendations to enhance tissue-transplantation safety. Tissue banks should validate processes and culture methods. Sterilization methods that do not adversely affect the functioning of transplanted tissue are needed to prevent allograft-related infections.
同种异体移植物常用于骨科重建手术。2001年,美国组织库分发了约87.5万个肌肉骨骼同种异体移植物。一名23岁男子因接受了来自组织库A的受污染同种异体移植物后死于索氏梭菌败血症,疾病控制和预防中心启动了一项调查,包括加强病例发现,调查组织回收、处理和检测所使用的方法。
同种异体移植物相关梭菌感染病例定义为1998年1月至2002年3月同种异体移植物植入后一年内手术部位经培养证实的感染。我们追踪组织至回收和处理这些组织的组织库。我们还估计了受牵连组织库处理的组织中梭菌感染的发生率和风险比,并审查了各组织库使用的处理和检测方法。
共识别出14例患者,他们均接受了组织库A处理的同种异体移植物。接受组织库A运动医学组织(即肌腱、股骨髁、半月板)的患者中梭菌感染率为0.12%,接受股骨髁的患者中感染率为0.36%。与其他组织库处理的组织相比,组织库A处理的组织发生梭菌感染的风险比估计值对于肌肉骨骼同种异体移植物、运动医学组织或肌腱为无穷大(P<0.001)。由于组织库A仅在用非杀芽孢抗菌溶液处理组织后才进行培养,一些检测结果可能为假阴性。尽管从其他解剖部位分离出梭菌或肠道菌群,或有其他受者感染的报告,但来自受牵连供者的组织仍被放行。
梭菌感染可追溯至同种异体移植物植入。我们提供临时建议以提高组织移植安全性。组织库应验证流程和培养方法。需要采用对移植组织功能无不利影响的灭菌方法来预防同种异体移植物相关感染。